PT  - JOURNAL ARTICLE
AU  - Arschang Valipour
AU  - Alvin Ing
AU  - Jonathan Williamson
AU  - Tajalli Saghaie
AU  - Daniel Steinfort
AU  - Lou Irving
AU  - Gregory Snell
AU  - Eli Dabscheck
AU  - William Krimsky
AU  - Jon Waldstreicher
AU  - Sebastian Fernandez-Bussy
TI  - Late Breaking Abstract - First-in-Human Results of Bronchial Rheoplasty: An Endobronchial Treatment For Chronic Bronchitis (CB)
AID  - 10.1183/13993003.congress-2018.OA2162
DP  - 2018 Sep 15
TA  - European Respiratory Journal
PG  - OA2162
VI  - 52
IP  - suppl 62
4099  - http://erj.ersjournals.com/content/52/suppl_62/OA2162.short
4100  - http://erj.ersjournals.com/content/52/suppl_62/OA2162.full
SO  - Eur Respir J2018 Sep 15; 52
AB  - Introduction: CB patients may benefit from ablation of mucus-producing airway cells. Bronchial Rheoplasty is a new procedure in which Pulsed Electric Fields are delivered to the airways via an endobronchial catheter. Preclinical studies demonstrated epithelial ablation and rapid regeneration with this technique.Methods: Patients with symptomatic CB underwent Bronchial Rheoplasty under general anesthesia, performed on the right-sided airways first, followed by left side treatment one month later. Endobronchial cryobiopsies were obtained before treatment and at follow up and evaluated by an independent blinded core lab. Changes in symptoms, quality of life and pulmonary function were assessed.Results: 25 patients with CB were enrolled (62.5% male, age 66.3±7.6 yrs, Post-BD FEV1 59.0±16.1%). There were no serious adverse events associated with Rheoplasty. Non-serious adverse events included COPD exacerbations (36% of patients), mild hemoptysis (40%), and dyspnea (12%). A reduction in goblet cell hyperplasia was measured in 63.6% of treated airways (p <0.01). Mean CAT and SGRQ scores at 6-months (n=13) were -7.8±9.1 points (p< 0.01) and -19.0±24.4 points (p<0.05), respectively. There were no significant changes in pulmonary function.Conclusion: Early results demonstrate safety and feasibility of Bronchial Rheoplasty in CB patients. Further studies are required to confirm these results.FootnotesCite this article as: European Respiratory Journal 2018 52: Suppl. 62, OA2162.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).